Illinois 2023-2024 Regular Session

Illinois House Bill HB2350 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1		-	Public Act 103-0030
2	1		HB2350 EnrolledLRB103 26427 BMS 52790 b HB2350 Enrolled LRB103 26427 BMS 52790 b
3	2		HB2350 Enrolled LRB103 26427 BMS 52790 b
4		-	AN ACT concerning regulation.
5		-	Be it enacted by the People of the State of Illinois,
6		-	represented in the General Assembly:
7		-	Section 5. The Illinois Insurance Code is amended by
8		-	changing Section 356u as follows:
9		-	(215 ILCS 5/356u)
10		-	Sec. 356u. Pap tests and prostate cancer screenings.
11		-	(a) A group policy of accident and health insurance that
12		-	provides coverage for hospital or medical treatment or
13		-	services for illness on an expense-incurred basis and is
14		-	amended, delivered, issued, or renewed after January 1, 2024
15		-	shall provide coverage, without imposing a deductible,
16		-	coinsurance, copayment, or any other cost-sharing requirement,
17		-	for all of the following:
18		-	(1) An annual cervical smear or Pap smear test for all
19		-	female insureds.
20		-	(2) An annual prostate cancer screening for male
21		-	insureds upon the recommendation of a physician licensed
22		-	to practice medicine in all its branches for:
23		-	(A) asymptomatic individuals men age 50 and over;
24		-	(B) African-American individuals men age 40 and
25		-	over; and
26		-	(C) individuals men age 40 and over with a family
	3	+	1 AN ACT concerning regulation.
	4	+	2 Be it enacted by the People of the State of Illinois,
	5	+	3 represented in the General Assembly:
	6	+	4 Section 5. The Illinois Insurance Code is amended by
	7	+	5 changing Section 356u as follows:
	8	+	6 (215 ILCS 5/356u)
	9	+	7 Sec. 356u. Pap tests and prostate cancer screenings.
	10	+	8 (a) A group policy of accident and health insurance that
	11	+	9 provides coverage for hospital or medical treatment or
	12	+	10 services for illness on an expense-incurred basis and is
	13	+	11 amended, delivered, issued, or renewed after January 1, 2024
	14	+	12 shall provide coverage, without imposing a deductible,
	15	+	13 coinsurance, copayment, or any other cost-sharing requirement,
	16	+	14 for all of the following:
	17	+	15 (1) An annual cervical smear or Pap smear test for all
	18	+	16 female insureds.
	19	+	17 (2) An annual prostate cancer screening for male
	20	+	18 insureds upon the recommendation of a physician licensed
	21	+	19 to practice medicine in all its branches for:
	22	+	20 (A) asymptomatic individuals men age 50 and over;
	23	+	21 (B) African-American individuals men age 40 and
	24	+	22 over; and
	25	+	23 (C) individuals men age 40 and over with a family
27	26
28	27
29	28
30	29		HB2350 Enrolled LRB103 26427 BMS 52790 b
31	30
32	31
33		-	history of or genetic predisposition to prostate
34		-	cancer.
35		-	(3) Surveillance tests for ovarian cancer for female
36		-	insureds who are at risk for ovarian cancer.
37		-	(b) This Section shall not apply to agreements, contracts,
38		-	or policies that provide coverage for a specified disease or
39		-	other limited benefit coverage.
40		-	(c) This Section does not apply to coverage of prostate
41		-	cancer screenings to the extent such coverage would disqualify
42		-	a high-deductible health plan from eligibility for a health
43		-	savings account pursuant to Section 223 of the Internal
44		-	Revenue Code.
45		-	(d) For the purposes of this Section:
46		-	"At risk for ovarian cancer" means:
47		-	(1) having a family history (i) with one or more
48		-	first-degree relatives with ovarian cancer, (ii) of
49		-	clusters of women relatives with breast cancer, or (iii)
50		-	of nonpolyposis colorectal cancer; or
51		-	(2) testing positive for BRCA1 or BRCA2 mutations.
52		-	"Prostate cancer screening" means medically viable methods
53		-	for the detection and diagnosis of prostate cancer, including
54		-	a digital rectal exam and the prostate-specific antigen test
55		-	and associated laboratory work. "Prostate cancer screening"
56		-	includes medically necessary subsequent follow-up testing as
57		-	directed by a health care provider, including, but not limited
58		-	to:
	32	+	HB2350 Enrolled- 2 -LRB103 26427 BMS 52790 b HB2350 Enrolled - 2 - LRB103 26427 BMS 52790 b
	33	+	HB2350 Enrolled - 2 - LRB103 26427 BMS 52790 b
	34	+	1 history of or genetic predisposition to prostate
	35	+	2 cancer.
	36	+	3 (3) Surveillance tests for ovarian cancer for female
	37	+	4 insureds who are at risk for ovarian cancer.
	38	+	5 (b) This Section shall not apply to agreements, contracts,
	39	+	6 or policies that provide coverage for a specified disease or
	40	+	7 other limited benefit coverage.
	41	+	8 (c) This Section does not apply to coverage of prostate
	42	+	9 cancer screenings to the extent such coverage would disqualify
	43	+	10 a high-deductible health plan from eligibility for a health
	44	+	11 savings account pursuant to Section 223 of the Internal
	45	+	12 Revenue Code.
	46	+	13 (d) For the purposes of this Section:
	47	+	14 "At risk for ovarian cancer" means:
	48	+	15 (1) having a family history (i) with one or more
	49	+	16 first-degree relatives with ovarian cancer, (ii) of
	50	+	17 clusters of women relatives with breast cancer, or (iii)
	51	+	18 of nonpolyposis colorectal cancer; or
	52	+	19 (2) testing positive for BRCA1 or BRCA2 mutations.
	53	+	20 "Prostate cancer screening" means medically viable methods
	54	+	21 for the detection and diagnosis of prostate cancer, including
	55	+	22 a digital rectal exam and the prostate-specific antigen test
	56	+	23 and associated laboratory work. "Prostate cancer screening"
	57	+	24 includes medically necessary subsequent follow-up testing as
	58	+	25 directed by a health care provider, including, but not limited
	59	+	26 to:
59	60
60	61
61		-	(1) urinary analysis;
62		-	(2) serum biomarkers; and
63		-	(3) medical imaging, including, but not limited to,
64		-	magnetic resonance imaging.
65		-	"Surveillance tests for ovarian cancer" means annual
66		-	screening using (i) CA-125 serum tumor marker testing, (ii)
67		-	transvaginal ultrasound, (iii) pelvic examination.
68		-	(Source: P.A. 102-1073, eff. 1-1-23.)
69		-	Section 99. Effective date. This Act takes effect January
70		-	1, 2025.
	62	+
	63	+
	64	+
	65	+	HB2350 Enrolled - 2 - LRB103 26427 BMS 52790 b
	66	+
	67	+
	68	+	HB2350 Enrolled- 3 -LRB103 26427 BMS 52790 b HB2350 Enrolled - 3 - LRB103 26427 BMS 52790 b
	69	+	HB2350 Enrolled - 3 - LRB103 26427 BMS 52790 b
	70	+	1 (1) urinary analysis;
	71	+	2 (2) serum biomarkers; and
	72	+	3 (3) medical imaging, including, but not limited to,
	73	+	4 magnetic resonance imaging.
	74	+	5 "Surveillance tests for ovarian cancer" means annual
	75	+	6 screening using (i) CA-125 serum tumor marker testing, (ii)
	76	+	7 transvaginal ultrasound, (iii) pelvic examination.
	77	+	8 (Source: P.A. 102-1073, eff. 1-1-23.)
	78	+	9 Section 99. Effective date. This Act takes effect January
	79	+	10 1, 2025.
	80	+
	81	+
	82	+
	83	+
	84	+
	85	+	HB2350 Enrolled - 3 - LRB103 26427 BMS 52790 b